A 7-page document developed by 2013 AVAC Fellow Oladayo Taiwo Oyelakin identifying challenges women face in access PMTCT services in Nigeria. This report used a community community consultation framework to identify barriers and provide recommendations.
Report of Community Consultation Among Young Women Living with HIV Currently Accessing PMTCT Services in Benue, Edo, Akwa-Ibom and Lagos States
HIV/AIDS in Uganda: 30 Years On! – A case for treatment as prevention approach
This report by 2012 AVAC Advocacy Fellow Alice Kayongo-Mutebi describes successes and challenges in a year-long campaign to expand access to antiretroviral treatment for HIV positive people in Uganda. It includes sections on the history of Uganda’s AIDS response, achievements in the work of a Ugandan civil society coalition seeking to improve ART access. It describes challenges and makes recommendations for future work.
Budgeting to End AIDS in Kenya: Accelerated ART Scale-Up is the Only Cost-Effective Option
This one-page draft issue brief illustrates the benefits of ART scale up on public health in Kenya. The report advocates for the commitment of reaching one million Kenyans by 2015 and shows the impact of this benchmark using CDC Kenya data.
What is Treatment as Prevention and What is it Not?
Simple, one-page factsheet developed in 2012 that defines treatment as prevention and what it can achieve.
Treatment as Prevention: Frequently asked questions
This FAQ was developed with input from the National Empowerment Network of People Living with HIV (NEPHAK) and Health GAP on the basis of national PLHIV dialogues on treatment as prevention conducted throughout Kenya. The questions and answers contain information relevant for a global audience—but have been written specifically for individuals living and working in low and middle income countries
Selected Trials of Long-Acting Injectables for Prevention and/or Treatment U=U of HIV
This Px Wire graphic from April-June 2014 Volume 7 No. 2 identifies selected trials of long-acting injectables in development for prevention and/or Treatment U=U of HIV.
Viral Load Testing Delivers Systemic Benefits from the Individual to the Institution
This graphic from AVAC Report 2013 highlights the benefits of routine viral load testing for both individuals and institutions. Expanding access to viral load testing is a key step toward achieving virologic suppression.
The Global HIV Treatment U=U Gap: Existing people on ART versus people eligible under past and current WHO guidelines
This year WHO released eagerly anticipated comprehensive antiretroviral Treatment U=U (ART) guidelines addressing how to optimize ART for both Treatment U=U and prevention. The guidance recommends raising the CD4 threshold for Treatment U=U initiation to 500 CD4 cells or below — with priority given to people who are symptomatic or have CD4 cell counts at or below 350. As this graphic from AVAC Report 2013 illustrates, this shift in guidelines will increase the gap between the number of people eligible for ART worldwide and those currently receiving it.
2013 WHO ARV guidelines can decrease new infections and deaths
WHO 2013 guidelines recommend initiating ART in HIV positive people with CD4 cell counts of 500 or below. This graphic from AVAC Report 2013 illustrates how implementing these guidelines will reduce infections and save lives.